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).a b s t r a c t
Prion diseases are a group of fatal neurodegenerative diseases caused by scrapie form of prion protein,
PrPSc. Prion protein (PrP) is bound to the cell via glycophosphatidylinositol (GPI) anchor. The role of GPI
anchor in PrPSc replication and propagation remains unclear. It has been shown that anchorless and
truncated PrP accelerate the formation and propagation of prions in vivo and further increases the risk for
transmission of prion diseases among species. To explain the role of anchorless forms of PrP in the
development of prion diseases, we have prepared ﬁve C-terminal PrP truncated variants, determined
their thermodynamic properties and analyzed the kinetics of conversion into amyloid ﬁbrils. According
to our results thermodynamic and kinetic properties are affected both by pH and truncation. We have
shown that the shortest variant was the most destabilized and converted faster than other variants in
acidic pH. Other variants converted with longer lag time of ﬁbrillization than WT despite comparable or
even decreased stability in acidic pH. Our results indicate that even the change in length for 1 amino acid
residue can have a profound effect on in vitro conversion.
© 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prion diseases are a group of fatal neurodegenerative disease.
They occur due to self-propagation and accumulation of patho-
logical form of prion protein, named prion (PrPSc). PrPSc is formed
by conversion of cellular form of prion protein (PrPC) [1]. PrPC is
anchored onto the membrane of most body cells with glyco-
phosphatidylinositol (GPI) anchor. The protein is expressed in most
tissues, where its role has not yet been fully explained. The path-
ological transformation of PrPC into PrPSc includes the protein's
secondary and tertiary structure changes, with no change in its
primary sequence. Consequently, the b-sheet rich PrPSc is formed.
PrPSc molecules are prone to aggregation in brain, which is asso-
ciated with neuron damage and loss of function.
The role of GPI anchor in PrPSc replication and propagation re-
mains unclear [2,3], but it has been recently shown on models of
transgenic mice, expressing only anchorless prion protein (PrP),nik@ztm.si (V. Curin Serbec).
r Inc. This is an open access articlethat anchorless PrP accelerates the formation and propagation of
prions [4e9] and further increases the risk for transmission of prion
disease among species [10].
Anchorless PrPs are a group of PrPs truncated at the C-terminus
and lack GPI anchor. Truncated forms can be generated from the
native form of PrP, using proteolytic degradation by ADAM pro-
teases [11,12], or can occur due to nonsensemutations [13e15]. One
such protein, PrP226*, was characterized using monoclonal anti-
body V5B2, which selectively recognizes the truncated form of PrP
ending with amino acids Tyr225 and Tyr226 [16]. A clinical study
made by Jansen et al. reported two cases of Gerstmann-Str€aussler
Scheinker syndrome (GSS) with deposition of C-terminally trun-
cated PrP, ending with Tyr226 and Gln227 [15]. The study serves as
conﬁrmation that anchorless truncated PrP can cause the formation
of disease in vivo.
Deposition of truncated PrPmolecules, besides PrPSc aggregates,
was described in the brain of patients with transmissible spongi-
form encephalopathies (TSEs) [13e15,17e19]. Using V5B2 it has
been shown that accumulation of PrP226* in the brain is charac-
teristic for most types of human TSEs, like GSS, sporadic
Creutzfeldt-Jakob disease (sCJD), variant Creutzfeldt-Jakob diseaseunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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bovine spongiform encephalopathy (BSE) and scrapie [20,21]. In
sCJD, the distribution of PrP226* correlates with the distribution of
PrPSc aggregates, therefore it could be acknowledged as a surrogate
marker for PrPSc [21].
The correlation between PrP226* and amyloid plaques suggests
that the truncated protein has an important role in the develop-
ment of amyloid diseases. According to previous studies, ﬁbrillation
can also be propagated by other anchorless PrPs, similar to PrP226*
[22,23]. Despite increasing evidence on the importance of trun-
cated PrP variants in vivo, these variants have not been character-
ized in vitro. In this study we investigate the effect of stop codon
mutations at the C-terminus on PrP stability and ﬁbrillization. We
prepared ﬁve C-terminal PrP truncated variants. The shortest
variant was the most destabilized and converted faster than other
variants in acidic pH. Other variants converted with longer lag time
of ﬁbrillization than WT despite comparable or even decreased
stability in acidic pH. Our results indicate that even the change in
length for 1 amino acid residue can have a profound effect on
in vitro conversion.2. Materials and methods
2.1. Preparation of PrP mutant constructs
We prepared ﬁve mutants of C-terminal truncated PrP. As a
template we used the plasmid pProExHTa, containing the
HuPrP(90e231, M129) gene [24], that was donated by prof. Giu-
seppe Legname (SISSA, Trieste, Italy). We prepared mutants Y225X,
Y226X, Q227X, R228X and G229X (Fig. 1) using the Quickchange kit
II XL Site-directed Mutagenesis (Agilent Tachnologies). Respec-
tively, we named the expressed proteins PrP224*, PrP225*, PrP226*,
PrP227* and PrP228*. The cloned DNA sequences were veriﬁed by
sequencing.Fig. 1. Schematic representation of the structure of human PrP (PDB ID 2LSB, up) [25]
and depicted amino acid residues (down) where we inserted stop mutations to prepare
truncated PrP variants.2.2. Protein expression, puriﬁcation and refolding
Plasmid pPROEXHTa encoding HuPrP mutants was transformed
into competent E. coli BL21 (DE3). The proteins were prepared as
previously described [24,25]. The isolated inclusion bodies were
solubilized in 6 M GndHCl and puriﬁed on a 5-mL FF Crude HisTrap
column (GE Healthcare). For spectroscopic and thermodynamic
studies mutants were refolded by dialysis against refolding buffer
(20 mM sodium acetate (pH 4.5) or 5 mM sodium phosphate (pH
7)). For studies of in vitro conversion of recombinant prion proteins,
mutants were dialyzed against 6 M GndHCl. Puriﬁed proteins were
analyzed using SDS-PAGE under reducing conditions.
2.3. Circular dichroism spectroscopy and thermal denaturation
Circular dichroism spectra were recorded on a Chirascan spec-
tropolarimeter (Applied Photophysics). Far-UV CD spectra were
recorded between 190 nm and 250 nm in a 1 mm path length
cuvette at a protein concentration of 0.2 mg/ml. Thermal denatur-
ation of truncated proteins were followed by measuring the CD
signal at 222 nm as a function of temperature with a heating rate of
1 C/min. The reversibility of refolding of denatured proteins to the
native state was assessed by recovery of CD signal.
As previously described, CD temperature scans were analyzed
by a 2-state transition model with a model equation that accounts
for the linear dependence of the pretranslational and posttransi-
tional baselines on temperature [26].
Differences in the stability were also analyzed as previously
described [27]. The relation of stability of truncated and wild type
(WT PrP) were estimated according to the relationship proposed by




, where DDG is the
difference in stability between truncated proteins and WT protein,
DTm is the difference in midpoint temperatures of truncated pro-
teins and WT PrP and DHwtm are reference enthalpy of WT PrP at
midpoint temperature Twtm . In case of the destabilization of WT PrP
by acidic pH, the reference values are from WT PrP at pH 7. A
negative value of DDG correlates to the destabilization of truncated
proteins with respect to WT PrP.
2.4. In vitro conversion of recombinant prion proteins
In vitro conversion was carried out as previously described
[27e29]. The denatured proteins were diluted into 1 M GndHCl,
3 M urea and 50 mM PBS (pH 7) or 20 mM sodium acetate with
100 mM NaCl (pH 4.5) to a ﬁnal protein concentration of 22 mM.
Conversion was conducted by shaking at 37 C, 1000 rpm. Shaking
was performed in 96-well microtiter plates with three 3/32 Teﬂon
balls per well. Formation of ﬁbrils was monitored using thioﬂavin T
(ThT). ThT emission (460e535 nm) was tracked by excitation at
442 nm at 5 mM ThT concentration with a Mithras LB 940 micro-
plate reader (Berthold Technologies) [27,29e31]. Kinetic data were






Y is the ﬂuorescence intensity, x is the time, and x0 is the time to
50% of maximal ﬂuorescence. Thus, the apparent rate constant,
kapp, for ﬁbril growth is given by 1/t and the lag time (tLAG) is given
by x0e2t. Each curve obtained from an individual experiment was
ﬁtted separately to extract kinetic parameters.
2.5. Analysis of ﬁbril formation
For analysis of in vitro conversion of prion protein we used
atomic force microscopy (AFM). Samples were prepared as previ-
ously described [31,34] and observed by Agilent Technologies 5500
Scanning Probe Microscope operating in acoustic alternating
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NanoWorld).
3. Results and discussion
In order to investigate the effect of C-terminal truncation of PrP
on thermal stability and ﬁbrillization propensity we inserted stop
mutations at positions Y225X, Y226X, Q227X, R228X and G229X of
human PrP (Fig. 1). Truncated variants PrP224*, PrP225*, PrP226*,
PrP227*, PrP228* and the full length human PrP (wild-type, WT)
were expressed in bacteria and isolated to purity.
From far-UV CD spectra we see that all mutants acquired a
globular form (Figs. 2A and 3A). The two minima at 210 nm and
222 nm suggest that all truncated proteins as WT PrP consist of
high content of a-helical structure. From comparison of far-UV CD
spectra of investigated proteins (Figs. 2A and 3A), we see that PrP
variants acquired a similar spectrum at both conditions. As re-
ported previously, decrease in pH results in formation of areas of
instability in PrP and conformational changes [33,35]. As the
spectra remain similar at both conditions, our results imply that
only minor changes in secondary structure occur.
The thermodynamic stability and ﬁbrillization propensity was
affected both by pH and truncation (Table 1, Figs. 2B, C, 3B and 3C).
As seen in Table 1 and Figs. 2B and 3B, the biggest destabilization
occurred to PrP224*, where the stability in respect to WT PrP was
decreased for 0.9 kJ/mol at pH 7 and 3.1 kJ/mol at pH 4.5. At the
change of pH from neutral to acidic, the stability of WT PrP was
decreased by 7 kJ/mol. The truncated proteins PrP225* and PrP226*
were also destabilized at both conditions, whereas PrP227* andFig. 2. Secondary structure (A), thermal stability (B) and conversion (C) of truncated prion p
PrP) at pH 7.PrP228* were destabilized at pH 4.5 and pH 7, respectively. As
already mentioned, decrease in pH locally affects the structure,
creating cores of destabilization [33,35], which could lead the
protein to unfold at lower Tm.
From Fig. 1 we see that amino acid residues 224e228 are part of
helix a3, which is positioned adjacent to loop b2a2. As previously
reported, helix a3 and loop b2a2 can form electrostatic and hy-
drophobic interactions with loop b2-a2 [37]. The loop is ﬂexible in
human PrP and consists of negatively charged amino acid residues
Asp167 and Glu168. When truncation occurs, the surface for for-
mation of hydrophobic interactions between helix a3 and loop b2-
a2 becomes smaller. Hydrophobic interactions are the core of
proper protein folding. The decrease in number of hydrophobic
interactions causes destabilization of structure, making it less
organized. This results in conformational changes as breakage of
helix structures, by which hydrophobic amino acid residues
become more accessible to solvents and interactions with other
molecules.
On the other hand an important role in protein stabilization is
given to electrostatic interactions, including H-bonds. Gln and Tyr
are polar molecules, which can form H-bonds with neighboring
amino acid residues. In WT PrP, Gln227, Tyr226 and Tyr225 are
incorporated in helix a3, but in PrP variants, the amino acid residue
that terminates the variant is more ﬂexible. Due to this property,
truncated helix a3 can approximate loop b2a2. Consequently
Gln227, Tyr226 and Tyr225 side chains can approach Asp167 and
Glu168 and form H-bods, which additionally stabilize the structure
and increase thermodynamic stability of the variant. At decrease of
pH to 4.5, a small amount of Asp and Glu in the structure becomeroteins PrP224*, PrP225*, PrP226*, PrP227*, PrP228* and wild type prion protein (WT
Fig. 3. Secondary structure (A), thermal stability (B) and conversion (C) of anchorless truncated prion proteins PrP224*, PrP225*, PrP226*, PrP227*, PrP228* and wild type prion
protein (WT PrP) at pH 4.5.
Table 1
Thermodynamic stability and kinetics of conversion of truncated prion proteins.
Tm (C) DHm (kJ/mol) DSm (J/Kmol) DDG (kJ/mol) t1/2 (h) kapp (h1)
PrP224* pH 4.5 56.0 204 618 0.9 27.0 0.4
pH 7 62.0 301 899 3.1 10.3 0.9
PrP225* pH 4.5 56.6 199 603 0.5 46.2 0.4
pH 7 63.7 247 732 1.6 11.6 0.9
PrP226* pH 4.5 56.0 261 793 0.9 65.8 0.2
pH 7 63.5 302 896 1.8 10.3 1.1
PrP227* pH 4.5 56.6 196 593 0.5 58.3 0.4
pH 7 66.7 258 759 1.0 10.7 0.9
PrP228* pH 4.5 58.0 191 577 0.2 49.0 0.2
pH 7 65.4 313 923 0.1 11.0 0.9
WT PrP pH 4.5 57.6 178 537 (7.0) 41.6 0.2
pH 7 65.6 298 880 e 10.5 1.0
DHm and DSm are values at Tm. Differences in thermodynamic stabilities between truncated and WT PrP were calculated using DDG ¼ DTm  DHwtm =Twtm (see Materials and
Methods). Errors in the thermodynamic parameters were between 5% and 10%. For midpoint transition time and growth rate the average errors were 2% and 18% respectively.
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destabilization of structure. Therefore as pH decreases, the PrP
variants become more destabilized than at neutral pH, but not as
destabilized as PrP224*. Since Ala is a small hydrophobic amino
acid, it is unable to form H-bonds with other amino acid residues.
Consequently PrP224* is found as the most thermodynamically
destabilized and has the highest ﬁbrillization propensity.
As we already mentioned, helix a3 terminates with Arg228.
Arginine is a polar charged molecule, which, on the surface, acts as
a promoter of appropriate folding by interaction with water sol-
vent. The water molecules that interact with Arg228 can therefore
form a shell around the polar amino acid residue, stabilizing the C-terminus and at the same time solubilize the protein. We presume
that helix a3 remains intact, which results in stabilities similar to
WT PrP.
Further we investigated how the destabilization caused by
truncation affected the ﬁbrillization propensity. Using the amyloid
speciﬁc dye ThT, wemonitored in vitro conversion to amyloid ﬁbrils
at mildly denaturing conditions. We presented results as time
dependent normalized ThT ﬂuorescence, which represents the
fraction of formed amyloid. Formation of amyloid ﬁbrils was
conﬁrmed in all cases, using AFM (Fig. S1). As previously reported
for WT PrP, at similar conversion conditions, amyloid ﬁbrils from
PrPs showed different morphological types, with average ﬁbril
V. Kovac et al. / Biochemical and Biophysical Research Communications 481 (2016) 1e6 5height ranging from 3 nm to 18 nm [36]. At pH 7 the differences in
ﬁbrillization between truncated forms in respect to WT PrP are
minor (Fig. 3B), but increase at pH 4.5. As seen in Table 1 and Fig. 3C,
at acidic pH only PrP224* conversionwas faster than that ofWT PrP,
which resulted in decreased lag time and higher growth rate. Under
the same conditions, other studied PrP variants have a longer lag
time of conversion than WT PrP. At decrease of pH to 4.5 PrP225*,
PrP226* and PrP227* intramolecular interactions between side
chains of terminating amino acid residues and loop b2a2 are still
present. This makes the C-terminus and loop of PrP variants less
available for intermolecular interactions, which results in pro-
longed lag time of conversion in respect to WT PrP. We presume,
that secondary structure of PrP228* remains similar to WT PrP. As
Arg228 additionally stabilizes the C-terminus of PrP228*, the
phenomenon could cause the delay in lag time of conversion in
respect to WT PrP. Intramolecular interactions between helix a3
and loop b2a2 are also present in WT PrP, leaving the ﬂexible C-
terminus available for intermolecular interactions (Fig. 1). We can
presume that, although truncation to a certain degree thermody-
namically destabilizes the studied proteins, intramolecular in-
teractions of C-terminus with loop b2a2 prolong the time of
in vitro conversion of PrP variants.
There have been reports of cases of human prion disease, which
developed because of expression of anchorless C-terminally trun-
cated PrP. The presence of one of the stop codon mutations Y145X,
Q160X, Y163X, Y226X or Q227X results in spontaneous neurolog-
ical illness, characterized by large PrP amyloid deposits [13e15,22].
The mentioned mutations in humans result in prion protein cere-
bral amyloid angiopathy (PrP-CAA) and GSS in case of Q227X,
anchorless PrPSc was also denoted in sCJD [38]. Interestingly, the
perivascular deposition in the case of Y145X, Y163X and Y226X is
similar to the distribution of PrP in transgenic mice expressing
anchorless PrP. As anchorless prions were found to accumulate in
non-neural tissues, their presence could raise concern for potential
spreading of anchorless PrP species to body ﬂuids and peripheral
tissues and further transmission.
From the data presented and information of previous studies
concerning anchorless and truncated forms of prion protein, we can
deduce that this family of molecules is somehow involved in for-
mation of amyloid disease. As their presence was previously found
and undoubtedly conﬁrmed in vivo, they can bemarked as potential
propagators or accelerators of amyloid disease. To conclude, the
studied PrP variants can be used as important targets for diagnosis
and planning of potential treatment of amyloid diseases, like
immunotherapy using scFv, derived from monoclonal antibody
V5B2 [39,40].
Acknowledgments
Authors gratefully acknowledge ﬁnancial support of the Slove-
nian Research Agency (Grant No. P4-0176), which also ﬁnances PhD
study of Valerija Kovac. Valerija Kovac is a PhD student at University
of Ljubljana, Faculty of Chemistry and Chemical Technology.
Abbreviations
AFM atomic force microscopy
BSE bovine spongiform encephalopathy
PrP-CAA prion protein cerebral amyloid angiopathy
CJD Creutzfeldt-Jakob disease
fCJD familial Creutzfeldt-Jakob disease
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